Research Analysts Set Expectations for CRBP Q3 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Research analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a report issued on Friday, August 7th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings of ($1.57) per share for the quarter, down from their prior forecast of ($1.26). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.87) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q4 2026 earnings at ($1.50) EPS, FY2026 earnings at ($6.11) EPS, FY2027 earnings at ($6.83) EPS, FY2028 earnings at ($5.56) EPS, FY2029 earnings at ($2.07) EPS and FY2030 earnings at $0.15 EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55).

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Guggenheim restated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Tuesday, May 26th. Mizuho cut their price target on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating on the stock in a report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. Finally, Wedbush decreased their price objective on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.12.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP opened at $9.46 on Tuesday. The stock has a market cap of $175.29 million, a price-to-earnings ratio of -1.53 and a beta of 2.59. The business has a 50 day simple moving average of $8.76 and a 200 day simple moving average of $9.06. Corbus Pharmaceuticals has a 52 week low of $7.12 and a 52 week high of $20.56.

Insiders Place Their Bets

In other Corbus Pharmaceuticals news, insider Nishant C. Saxena bought 9,000 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $7.58 per share, with a total value of $68,220.00. Following the acquisition, the insider directly owned 75,300 shares of the company’s stock, valued at $570,774. This represents a 13.57% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John Kenneth Jenkins sold 4,800 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a total value of $37,968.00. Following the completion of the sale, the director directly owned 3,833 shares of the company’s stock, valued at $30,319.03. This represents a 55.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 38,238 shares of company stock worth $365,393. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CRBP. Orbimed Advisors LLC grew its holdings in shares of Corbus Pharmaceuticals by 8.8% during the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after purchasing an additional 140,000 shares in the last quarter. Exome Asset Management LLC raised its stake in shares of Corbus Pharmaceuticals by 67.8% in the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after purchasing an additional 94,593 shares in the last quarter. Seven Fleet Capital Management LP raised its stake in shares of Corbus Pharmaceuticals by 51.0% in the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 28,937 shares in the last quarter. Bank of America Corp DE lifted its position in Corbus Pharmaceuticals by 53,592.3% in the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 13,934 shares during the period. Finally, Royal Bank of Canada lifted its position in Corbus Pharmaceuticals by 81.2% in the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 13,401 shares during the period. Institutional investors and hedge funds own 64.64% of the company’s stock.

More Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, implying substantial potential upside from recent trading levels despite reducing its earnings forecasts. Analysts continue to view Corbus’ pipeline, including lenabasum for inflammatory and fibrotic diseases, as a potential long-term catalyst. HC Wainwright Cuts Corbus Pharmaceuticals Price Target
• Neutral Sentiment: Institutional ownership remains high at approximately 64.6%, with several investment firms increasing their positions in the latest reported quarter. However, these holdings are based on historical filings and may not reflect current positioning.
• Negative Sentiment: HC Wainwright materially lowered its EPS outlook across multiple years: 2026 to -$6.11 from -$4.99, 2027 to -$6.83 from -$5.66, 2028 to -$5.56 from -$4.58, and 2029 to -$2.07 from -$1.13. Its 2030 forecast was reduced to just $0.15 from $1.29, while third- and fourth-quarter 2026 loss estimates also widened.
• Negative Sentiment: Analysts have recently reduced price targets, including HC Wainwright to $35 from $40 and Oppenheimer to $48 from $52. Although both firms retain bullish ratings, the cuts suggest lower near-term expectations. Oppenheimer Cuts Corbus Pharmaceuticals Price Target
• Negative Sentiment: Insider selling adds to investor caution. CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at an average of $10.08, reducing their direct holdings by approximately 9.75% and 12.41%, respectively. Sean Moran Sells Corbus Pharmaceuticals Stock
• Negative Sentiment: Corbus’ latest quarterly results showed a loss of $1.81 per share, wider than the $1.26 analyst consensus, reinforcing concerns about ongoing cash burn and the path to profitability.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.